Canine lymphoma is one of the most common cancers in dogs. While some breeds appear more at risk than others, all can be affected. Although it is often treatable, canine lymphoma can rarely be cured. A continued understanding of the mechanisms causing lymphoma in dogs and identification of novel therapies are needed to improve survival in dogs with lymphoma.
Diagnostic tests based on the detection of DNA from harmful organisms in clinical samples have revolutionized veterinary medicine in the last decades. Currently, diagnostic panels for several vector-borne organisms are available through universities and private labs in the USA and abroad. However, the vast majority of results from sick dogs are negative, which frustrates veterinarians and dog owners trying to reach a definitive diagnosis.
Identification of Novel Synthetic Lethal Partners to Optimize PI3K Targeted Therapies in Canine Hemangiosarcoma
Hemangiosarcoma (HSA) is a cancer of the cells lining the blood vessels that is very aggressive and has nearly always spread by the time it is diagnosed. HSA accounts for 5-7% of all cancers in dogs resulting in approximately 25,000-50,000 new cases per year.
Dirofilaria immitis is the nematode parasite that causes heartworm disease in the United States. Heartworm infection causes severe pathology and suffering in dogs and cats. Until recently, heartworm infection was a preventable disease due to the availability of effective monthly preventative treatments.
The Role of Complex Translocations Associated with TP53 Somatic Mutations for Aiding Prognosis of Canine Diffuse Large B cell Lymphoma When Treated with Standard of Care CHOP Chemotherapy
Lymphoma accounts for up to 24% of all cancers diagnosed in pet dogs. Among these cases diffuse large B-cell lymphoma (DLBCL) is the most common subtype. Despite continued advances in veterinary medicine, the response to treatment for canine lymphoma remains highly variable with no reliable means to predict response.
Targeting the Cancer Epigenome: The Effect of Specific Histone Lysine Methyltransferase Inhibition in Canine B-Cell Lymphoma
Canine lymphoma is one of the most common cancers in dogs. While some breeds appear more at risk than others, all can be affected. While often treatable, canine lymphoma can rarely be cured. A continued understanding of the mechanisms causing lymphoma in dogs and identification of novel therapies are needed to improve survival in dogs with lymphoma.
Epilepsy is the most common nervous system disorder of dogs, affecting up to 0.75% of the canine population. Approximately one-third of dogs with epilepsy fail to achieve adequate seizure control with anti-seizure medication. This study aims to evaluate the role of certain intestinal bacteria in the management of epilepsy in dogs. Alterations
Epilepsy is one of the most common neurologic diseases of dogs and a top concern of dog breeders. Despite strong evidence that genetics is important in determining the risk of idiopathic epilepsy, numerous gene mapping studies have failed to identify a locus that accounts for that risk in either dogs or humans. Seizures occur when
Epilepsy is the most common neurologic condition in dogs. Approximately 20-30% of dogs receiving standard therapy remain uncontrolled for their seizures. Additionally, the side effects of the antiepileptic drugs (AED) are often unacceptable. Thus, there is a need for an AED that is efficacious with minimal side effects. Cannabidiol
Lymphoma is the most common malignancy of dogs representing up to 25% of diagnosed cancers. Dogs often develop an aggressive form of lymphoma that is rarely curable, with most unfortunately succumbing to disease within 12 months of diagnosis despite best-available chemotherapies. Dr. Wilson will develop a new treatment to re-train the dog’s own immune system to attack the most common type of canine lymphoma, B-cell lymphoma.